Agents such as nivolumab and pembrolizumab, monoclonal antibodies that block PD-1 and ipilimumab, a CTLA-4 inhibitor, have demonstrated good responses in HCC patients (Zhang et al., 2022a). Here, PDCD1 is linked to hepatocellular carcinoma.